PMID- 35582860 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1744-764X (Electronic) IS - 1474-0338 (Linking) VI - 21 IP - 12 DP - 2022 Dec TI - Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review. PG - 1505-1510 LID - 10.1080/14740338.2022.2078301 [doi] AB - BACKGROUND: Although cardiac disorder-related adverse events (AEs) have been reported in patients treated with aryl hydrocarbon receptor (AHR) agonists, their safety profiles remain unknown. Here, we identified significant cardiac disorders associated with AHR agonists and further evaluated their relevance. RESEARCH DESIGN AND METHODS: Database queries were performed using OpenVigil 2.1 and AEs voluntarily submitted to Food and Drug Administration Adverse Event Reporting System (FAERS) between 2004 and 2020 were included. This study based on the Medical Dictionary for Regulatory Activities and the standardized MedDRA Queries to define the preferred terms, and we used reporting odd ratio to detect signals. RESULTS: In the FAERS database, 14,078 cardiac disorder-related AEs were identified in patients receiving AHR agonists. Among all AHR agonists, the number of cardiac disorder-related PTs with positive signals for AHR agonists was 93. Peripheral swelling (n = 1572) and atrial fibrillation (n = 1277) were the most reported cardiac disorder-related AEs among AHR agonists in disproportionately reported PTs. Moreover, several AHR agonists were highly associated with tachyarrhythmia. CONCLUSIONS: By mining the FAERS database, we provided more information on the association between AHR agonist use and cardiac disorder-related AEs. FAU - Tian, Xiaoxue AU - Tian X AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Zheng, Shufen AU - Zheng S AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Wang, Jing AU - Wang J AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Yu, Meiling AU - Yu M AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Lin, Zhuoheng AU - Lin Z AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Qin, Min AU - Qin M AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Wu, Yuanyuan AU - Wu Y AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Chen, Shiyu AU - Chen S AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. FAU - Zhong, Shilong AU - Zhong S AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. AD - School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. AD - Department of Cardiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. LA - eng PT - Journal Article DEP - 20220527 PL - England TA - Expert Opin Drug Saf JT - Expert opinion on drug safety JID - 101163027 RN - 0 (Receptors, Aryl Hydrocarbon) SB - IM MH - Humans MH - *Adverse Drug Reaction Reporting Systems MH - *Heart Diseases/chemically induced/epidemiology MH - Pharmacovigilance MH - *Receptors, Aryl Hydrocarbon/agonists MH - United States MH - United States Food and Drug Administration OTO - NOTNLM OT - AHR agonists OT - FAERS OT - adverse events OT - cardiac disorders OT - tachyarrhythmia EDAT- 2022/05/19 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/05/18 04:03 PHST- 2022/05/19 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/05/18 04:03 [entrez] AID - 10.1080/14740338.2022.2078301 [doi] PST - ppublish SO - Expert Opin Drug Saf. 2022 Dec;21(12):1505-1510. doi: 10.1080/14740338.2022.2078301. Epub 2022 May 27.